AzTrials
AzTrials

Fluid OverloadDeepCARTNCT06899880

Perfusion Parameters and Outcome During a Standardized Deresuscitation Strategy with Net Ultrafiltration: a Retrospective Cohort Study.

An observational study of Fluid Overload and Acute Kidney Injury, run by Hospices Civils de Lyon at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hemodynamic tolerance of fluid removal during deresuscitation is a cornerstone of the impact on outcome of such a strategy. However, how to define and to predict hemodynamic tolerance to fluid removal remains controversial. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.
How many people
120 participants
Where
1 siteFrance
Study dates
1 Jan 2024to 1 Apr 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: adults' patients with fluid overload and continuous renal replacement therapy in intensive care unit

Who may be able to join

  • Age ≥ 18 years old
  • Acute kidney injury requiring continuous renal replacement therapy
  • Standardized deresuscitation following a routine care protocol

Who cannot join

  • Chronic hemodialysis
  • Advanced directives to withhold or withdraw life-sustaining treatment,
  • Patient's opposition to the use of his/her personal health data

Trial locations and contacts

1 site in 1 country.

France1 site
  • Louis Pradel Hospital

    France, Bron, 69500

Other trials in France

About this study

Hemodynamic tolerance of fluid removal during deresuscitation is a cornerstone of the impact on outcome of such a strategy. However, how to define and to predict hemodynamic tolerance to fluid removal remains controversial. The investigators routinely use a standardized deresuscitation protocol in patients with fluid overload and continuous renal replacement therapy combined with monitoring of clinical and biological perfusion parameters.

The aim of the study was to describe perfusion during deresuscitation, and to determine whether it is associated with major adverse kidney events at day 30.

Being tested
Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.
Medical subject headings
Edema, Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.Other

    Arterial lactate, pCO2 gap, SvO2, capillary refill time and mottling score anomalies will be described during the first 5 days of the deresuscitation strategy.

Study groups in NCT06899880
Study groupRoleWhat they receive
Standardized deresuscitation strategyEligible patients without hypoperfusion benefited from: 1) a restrictive approach of intakes combining hypercaloric enteral or per os feeding with hydric restriction as much as possible and no fluid of maintenance, and 2) a systematic UFnet of 2 mL/kg/h until reaching dry weight and a systematic monitoring every 6 h of: peripheral perfusion by capillary refilling time and mottling score, arterial lactate level, and central venous oxygen saturation.
Receives: Other: Describe the perfusion parameters during a deresuscitation strategy and their association with the outcome.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MAKE 30

    Major adverse kidney event at day 30, defined as follows:

    • Death OR
    • No weaning of renal replacement therapy OR
    • Serum creatinine > 2 times baseline serum creatinine

    Measured: A day 30 after the initiation of the deresuscitation strategy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2025
  2. Study start1 Jan 2024
  3. Primary completion1 Mar 2024
  4. Study completion1 Apr 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06899880
Sponsor's protocol ID
24-5563
Acronym
DeepCART
Status last verified
Mar 2025
First submitted
21 Mar 2025
Last updated
28 Mar 2025
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Fluid Overload and Acute Kidney Injury, run by Hospices Civils de Lyon at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MAKE 30 (time frame: A day 30 after the initiation of the deresuscitation strategy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in